Clinical Trial With MSC for Graft Versus Host Disease Treatment
Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
Sequential administration of MSCs obtained from adipose tissue is an effective and safe
treatment for acute graft versus host disease refractory to first-line treatment. Furthermore
the infusion of these cells produces a biological pattern in patients that relates to the
clinical response.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud